Philippe Camus, M.D.

Dijon, France

Back

The Drug-Induced Respiratory Disease Website

VII.a

VII - Cardiotoxicity

‘Cardiotoxicity’

Last update 17/06/2026

The broad term 'cardiotoxicity' encompasses several entities and patterns of cardiac injury including subclinical change in LVEF or cardiac biomarkers, cardiomyopathy, heart failure, AV heart block, conduction abnormalities, myocarditis, myocardial fibrosis, dysrrhythmias, pericarditis, pericardial effusion, tamponade, syncope, cardiac/cardiopulmonary arrest and/or valvular heart dysfunction or disease. Pulmonary edema and pleural effusion may be the annunciating signs and symptoms of cardiotoxicity (PMID 1403060). Cardiotoxicity is a significant hurdle of novel anticancer agent use including the immune checkpoint inhibitors (PMID 25210198, 25574894, 27732808, 29912044, 29980467, 30433897). Can be life-threatening or fatal (PMID 29980467)

Causative drugs

31
Abiraterone
II.a
VII.a
X.a
X.d
Anabolic androgenic steroids
I.a
III.a
III.b
VI.a
VI.b
VII.a
X.a
XII.b
XIII.f
XVI.e
XXII.b
XXIV.y
XXXVIII.h
Anagrelide
I.a
VI.a
VII.a
XII.b
XV.a
Anthracyclines
II.a
II.h
VI.a
VII.a
X.a
Anti-angiogenesis/-angiogenic agents
VII.a
Antimalarial drugs - Antimalarials
II.a
VII.a
XXIII.a
Arsenic trioxide (As2O3)
VII.a
X.b
X.d
X.i
XII.b
XIV.a
XVI.e
XXII.b
XXIV.a
Atezolizumab
I.m
V.a
VII.a
XIV.a
XV.e
XXIV.a
XXIV.b
XXXVI.b
XXXVI.f
XXXVI.ac
Bevacizumab
II.a
VI.a
VI.c
VII.a
XI.a
XIII.a
XIII.o
XIV.k
XVI.e
XVI.i
XVI.j
XVI.o
XVIII.d
XX.d
XXII.b
XXIV.a
XXIX.a
XXXVI.f
CAR T-cell therapy
I.a
I.f
I.g
I.l
II.a
II.c
II.d
II.e
III.c
III.g
VI.a
VII.a
X.b
X.c
XII.b
XIII.a
XIV.a
XVI.i
XXII.b
XXIV.k
XXXVI.y
Capecitabine
III.a
III.c
V.a
VII.a
XV.a
XXI.a
XXIV.s
XXXVI.c
Carfilzomib
II.a
VI.a
VII.a
XI.a
XVI.e
XXIV.a
XXIV.b
XXXIX.a
Clozapine
V.a
V.b
VI.a
VII.a
XII.n
XIII.a
XXIV.a
XXVIII.a
XXIX.a
XXXIII.b
XXXIII.c
Crizotinib
I.e
VII.a
XXII.b
XXIV.a
Cyclophosphamide (i.v infusional)
VII.a